Future Science Group
nnm-2021-0179 table S2.docx (13.45 kB)

Supplemental Table 2. Activity of ASO targeting RBD or BCL-xL in B16F10, A375 and 132N1 cells

Download (13.45 kB)
posted on 2021-07-23, 08:32 authored by Figshare Future Science GroupFigshare Future Science Group, Robert K. DeLong, Ryan Swanson, Megan C. Niederwerder, Pratiksha Khanal, Santosh Aryal, Ramesh Marasini, Majid Jaberi-DourakiMajid Jaberi-Douraki, Heman Shakeri, Reza MazloomReza Mazloom, Sarah Schneider, Steve Ensley, Lane L. Clarke, Rowena A. Woode, Sarah YoungSarah Young, Sagar Rayamajhi, Tracy Miesner, Mary Lynn Higginbotham, Zhoumeng Lin, Tej Shrestha Kartik Ghosh, Garry Glaspell, Elza N. Mathew


Aims: To investigate the distribution, tolerance, and anticancer/antiviral activity of Zn-based physiometacomposites (PMCs). Methods: Manganese, iron, nickel and cobalt doped ZnO, ZnS or ZnSe were synthesized. Cell uptake, distribution into 3-D culture and mice, biochemical and chemotherapeutic activity were studied by fluorescence/bioluminescence, confocal microscopy, flow cytometry, viability, antitumor and virus titer assays. Results: Luminescence and inductively coupled plasma mass spectrometry analysis showed that nanoparticle distribution was liver>spleen>kidney>lung>brain, without tissue or blood pathology. Photophysical characterization as ex vivo tissue probes and LL37 peptide, antisense oligomer (ASO) or aptamer delivery targeting RAS/RBD. 25 µg/ml 48-hour treatment showed >98-99% cell viability, 3-D organoid uptake, 3-log inhibition of β-Galactosidase and porcine reproductive respiratory virus infection. Conclusions: Data support the preclinical development of PMCs for imaging and delivery targeting cancer and infectious disease.


Funding This work was supported by NSF RAPID grant (2029579) to RKD, MN and SA and CF Foundation Pilot award (CLARKE19XX0) to LC and RKD.